Loading...
PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2?
Poly(ADP-ribose) polymerase (PARP) inhibitors have been explored as therapeutic agents for the treatment of hereditary breast and ovarian cancers harboring mutations in BRCA1 or BRCA2. In a new study, Inbar-Rozensal and colleagues show that phenanthridine-derived PARP inhibitors promote cell cycle a...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
BioMed Central
2009
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2815546/ https://ncbi.nlm.nih.gov/pubmed/20017885 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/bcr2451 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|